Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcÎ³RIIB Cross-Linking.

Liu, Luyan; Wu, Yi; Ye, Kaiyan; Cai, Meichun; Zhuang, Guanglei; Wang, Jieyi

Liu, Luyan; Wu, Yi; Ye, Kaiyan; Cai, Meichun; Zhuang, Guanglei; Wang, Jieyi.

Afiliación

Liu L; Lyvgen Biopharma, Shanghai, China.
Wu Y; Lyvgen Biopharma, Shanghai, China.
Ye K; State Key Laboratory of Oncogenes and Related Genes, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cai M; Shanghai Key Laboratory of Gynecologic Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhuang G; State Key Laboratory of Oncogenes and Related Genes, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wang J; Shanghai Key Laboratory of Gynecologic Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Front Pharmacol ; 13: 924197, 2022.

Article en En | MEDLINE | ID: mdl-35865955

Palabras clave

CD137 (4-1BB); CD40; FcÎ³RIIB; TNFRSF; agonist; cancer; cross-linking; immunotherapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google